10 Most Undervalued Pharma Stocks to Buy Now

3. Novartis AG (NYSE:NVS)

P/E Ratio: 16.74 

Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on developing innovative treatments across oncology, immunology, neuroscience, cardiovascular, and renal diseases. The company continues to invest heavily in research and development, aiming to deliver breakthrough medicines that improve patient outcomes worldwide.

The company’s Kisqali (ribociclib) has emerged as a major growth driver, with Q2 2025 sales surging 64% globally and 100% in the U.S. It targets metastatic breast cancer and is positioned as a potential blockbuster. Other notable therapies include Pluvicto for prostate cancer and Scemblix for chronic myeloid leukemia, both showing strong commercial momentum.

Novartis AG (NYSE:NVS) is expanding its presence in nephrology. Vanrafia (atrasentan) recently received FDA accelerated approval for reducing proteinuria in IgA nephropathy, marking a key advancement. Fabhalta (iptacopan), an oral treatment for C3 glomerulopathy, also gained approval. Ongoing trials include zigakibart, a Phase III candidate for IgAN, with results expected in 2026.

The business introduced Coartem Baby, a pediatric malaria treatment approved by Swissmedic. It addresses the unmet need for infants under 5 kg with a cherry-flavored, easily dissolvable formulation. Novartis AG (NYSE:NVS) plans to launch it on a not-for-profit basis in malaria-endemic regions.

The corporation has streamlined its pipeline around core therapeutic areas, with several Phase III trials in progress. These include remibrutinib for autoimmune diseases, ianalumab for lupus, and YTB323 for neuroimmunological disorders. The company expects 15 submission-enabling data readouts over the next two years, which underscores a robust late-stage pipeline.